GlassScriptPhysician profile
Annelise Wilhite
NPI 1407218852
$2,891.07
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $133 · 2022: $825 · 2023: $1,324 · 2024: $610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,864 · Education: $70.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,863.58 |
| Education | $70.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $520.86 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $332.28 | 2022-2024 | Lynparza, Imfinzi, Enhertu |
| Regeneron Healthcare Solutions, INC. | $256.09 | 2022-2024 | Libtayo |
| Janssen Biotech, INC. | $240.09 | 2022-2024 | Erleada, Akeega, Balversa |
| Abbvie INC. | $179.27 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $133.26 | 2023-2024 | Iclusig, Alunbrig, Ninlaro |
| Lilly USA, LLC | $127.63 | 2021-2023 | Verzenio, Retevmo |
| Incyte Corporation | $123.13 | 2022 | |
| Merck Sharp & Dohme LLC | $117.53 | 2022-2024 | Keytruda, Lynparza, Reblozyl |
| Myriad Genetic Laboratories, INC. | $101.85 | 2023 | Myrisk |
| Seagen INC. | $100.45 | 2022-2023 | Tivdak |
| Exelixis INC. | $62.22 | 2023-2024 | Cabometyx |
| Genzyme Corporation | $58.58 | 2023-2024 | |
| Dendreon Pharmaceuticals LLC | $49.36 | 2022 | |
| Novartis Pharmaceuticals Corporation | $39.48 | 2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $35.17 | 2023 | Tivdak |
| Pharmaessentia USA Corporation | $35.10 | 2023 | Besremi |
| Stemline Therapeutics INC. | $34.06 | 2023 | Orserdu |
| Immunogen, INC. | $32.49 | 2023 | Elahere |
| Amgen INC. | $32.29 | 2022 | |
| Mirati Therapeutics, INC. | $32.28 | 2023-2024 | Krazati |
| Puma Biotechnology, INC. | $30.04 | 2023 | |
| Myovant Sciences INC. | $25.11 | 2022 | |
| Blueprint Medicines Corporation | $20.90 | 2023 | Ayvakit |
| Glaxosmithkline, LLC. | $18.36 | 2023 | Zejula, Jemperli |
| Pharmacosmos Therapeutics INC. | $18.11 | 2023 | Monoferric |
| Tersera Therapeutics LLC | $17.28 | 2023 | Zoladex |
| Aveo Pharmaceuticals, INC. | $15.82 | 2023 | Fotivda |
| Genentech USA, INC. | $15.65 | 2023 | Polivy, Lunsumio |
| Rigel Pharmaceuticals, INC. | $15.60 | 2022 | |
| Daiichi Sankyo INC. | $14.74 | 2022 | |
| Karyopharm Therapeutics INC. | $14.48 | 2023 | Xpovio |
| Cumberland Pharmaceuticals, INC. | $14.10 | 2024 | Sancuso |
| Adc Therapeutics America, INC. | $13.95 | 2022 | |
| Alexion Pharmaceuticals, INC. | $13.46 | 2023 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Annelise Wilhite listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.